Developer docs
API playgroundTry for free, no card

Search company profiles

Genflow Biosciences

Full company profile

uuid00002xe

Namestring
Genflow Biosciences
Legal namestring
Genflow Biosciences plc
Websiteurl
genflowbio.com
Company typeenum
Public
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGosselies, Belgium
HQ citystring
Gosselies
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, longevity therapeutics, age-related disease treatment, SIRT6 gene therapy, veterinary longevity
Industry4 codes
PRIMARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAMANAD
Cell & Gene Therapy for Veterinary Regeneration
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy / Longevity Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Human Gene Therapy (GF-1002)
TypeOne Time License
Description

Pre-revenue biotech developing SIRT6 gene therapies targeting age-related diseases including MASH, Werner Syndrome, and sarcopenia. Revenue expected from therapeutic product sales upon regulatory approval.

defenseworld.net
2Animal Health / Veterinary Gene Therapy
TypeOne Time License
Description

Commercialization of canine SIRT6 gene therapy (GF-1004) for companion animal aging. The company is actively pursuing licensing and co-development discussions with Tier-1 animal health companies. Potential for direct commercialization or licensing deals.

stocktitan.net
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Genflow Biosciences develops gene therapy candidates that deliver a centenarian variant of the SIRT6 gene via AAV vectors to slow or reverse hallmarks of aging in humans and dogs. Its lead human candidate, GF-1002, targets MASH and other age-related conditions, while GF-1004 is a canine SIRT6 gene therapy evaluated in the SLAB aged-beagle clinical study. The company is pre-revenue and intends to monetize these candidates through licensing and co-development deals with pharmaceutical and animal health partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • All treatment groups in the SLAB study demonstrated superior survival compared to control animals, with no adverse events observed across dosing periods.
+3 more records
Product overview1 text field

Genflow Biosciences is a longevity bioscience company developing gene therapies targeting the aging process through delivery of centenarian SIRT6 gene variants. The company's core product portfolio includes GF-1002 (lead gene therapy for MASH targeting humans), GF-1004 (canine-compatible SIRT6 gene therapy for dog longevity), and the SLAB clinical program evaluating the therapy in aged beagles. The company operates through its SIRT6 mRNA payload platform delivered via lipid nanoparticle (LNP) technology, with clinical programs spanning human MASH treatment, veterinary longevity, muscular diseases (sarcopenia, frailty), and glaucoma. Founded in 2020, the company is headquartered in London with R&D facilities in Belgium and a US office in Cambridge, MA.

Product and service4 records
1GF-1002
CategoryHuman gene therapy
Description

Lead gene therapy candidate delivering a centenarian variant of the SIRT6 gene via AAV for the treatment of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in human patients with advanced fibrosis. Targeted at pharmaceutical partners for licensing and co-development.

2GF-1004
CategoryVeterinary gene therapy
Description

Proprietary canine-compatible SIRT6 gene therapy for addressing age-related decline, sarcopenia, and longevity in companion dogs. Evaluated in the SLAB clinical study and targeted at Tier-1 animal health partners for licensing or co-development.

3SLAB Clinical Program (Sarcopenia and Longevity in Aged Beagles)
CategoryVeterinary clinical program
Description

Proof-of-concept clinical trial program evaluating SIRT6 centenarian gene therapy in 24 aged beagle dogs to assess safety, biological activity, muscle mass preservation, frailty index reduction, and quality-of-life endpoints. Run with Syngene as contract research organisation.

4SIRT6 mRNA Payload with Acuitas LNP Delivery
CategoryTechnology platform / Delivery system
Description

Technology platform combining Genflow's SIRT6 mRNA payload with Acuitas' proprietary lipid nanoparticle (LNP) delivery system for preclinical evaluation studies supporting future development decisions and partnering arrangements.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1CER Groupe
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-30
Description

Partnership with CER Groupe (Centre d'Enseignement et de Recherche sur les Animaux de Laboratoire) established to support pre-IND development activities for the company's gene therapy programs.

stocktitan.net
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-30
Description

Partnership with Heureka Labs established to support pre-IND development activities for the company's gene therapy programs.

3Tier-1 Global Animal Health Companies
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Genflow expanded its engagement with Tier-1 global animal health companies by entering additional confidentiality agreements for the ongoing review of data from its canine SIRT6 gene therapy programme. The expansion follows positive preliminary interim results reported in February 2026 and reflects a broadening base of third-party evaluation of the company's data and underlying technology. These interactions are exploratory in nature and support an ongoing evaluation process for potential licensing and co-development.

stocktitan.net
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-20
Description

Strategic technology collaboration with Acuitas Therapeutics, a Vancouver-based leader in lipid nanoparticle (LNP) delivery systems, to integrate Acuitas' proprietary LNP platform with Genflow's SIRT6 mRNA payload for preclinical evaluation studies. The collaboration is fully funded by Acuitas with no cash consideration or dilution to Genflow shareholders, representing independent validation of Genflow's proprietary science. Data generated from preclinical studies will inform future development decisions including delivery optimization and potential partnering arrangements for Genflow's SIRT6 platform targeting age-related diseases.

5Syngene
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-01-01
Description

Syngene, an independent contract research organisation, manages the dog's longevity clinical trial for Genflow. The trial is controlled, randomised and includes both aesthetic and biological endpoints, running for one year with six months of treatment followed by six months of assessment.

genflowbio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing senolytic therapeutics for age-related ophthalmologic and musculoskeletal diseases. Comparable aging-disease pipeline orientation and small-cap biotech profile, though Unity's modality is small-molecule rather than gene therapy.

TypeEmerging player
Description

Clinical-stage biotech developing in vivo gene editing therapies for cardiovascular disease, including MASH-relevant metabolic indications. Comparable in vivo genetic medicine approach and cardiometabolic disease focus, with a gene-editing rather than gene-replacement modality.

TypeBroad incumbent
Description

Commercial-stage leader in AAV-based gene therapies for rare genetic diseases. Comparable modality (AAV gene therapy), regulatory pathway (rare disease), and platform-extension logic, though operating at commercial scale versus Genflow's pre-clinical stage.

TypeDirect peer
Description

Gene therapy company developing AAV-delivered interventions targeting age-related disease in dogs and other species. Highly comparable to Genflow given shared modality (AAV gene therapy), shared target species (canine), and shared thesis (treating aging biology rather than single diseases).

TypeBroad incumbent
Description

Well-capitalized private biotech pursuing cellular reprogramming to restore cellular health and reverse disease. Overlapping mission in treating fundamental aging biology, though operating at materially greater scale and with a different core modality.

TypeDirect peer
Description

Clinical-stage veterinary pharmaceutical company developing drugs (LOY-001, LOY-002) to extend healthspan and lifespan in dogs. Direct peer given Genflow's GF-1004 canine SIRT6 longevity program and shared focus on the companion-dog longevity market.

TypeDirect peer
Description

Clinical-stage biotech identifying drug targets through analysis of human aging biology and developing therapeutics for age-related metabolic and inflammatory diseases. Direct peer given shared 'aging-as-indication' thesis and pipeline of age-related disease programs.

TypeBroad incumbent
Description

Commercial-stage gene editing company with approved therapy and pipeline spanning rare genetic and regenerative medicine indications. Comparable genetic medicine modality and rare-disease pipeline focus, though at far greater scale and with different editing chemistry.

TypeBroad incumbent
Description

Alphabet-backed R&D organization focused on understanding the biology of aging and translating insights into therapeutics. Comparable long-horizon aging biology focus, but operates at significantly larger scale and with broader scope than Genflow.

TypeBroad incumbent
Description

Clinical-stage gene therapy company with proprietary AAV delivery platform and approved/in-development rare-disease programs. Comparable AAV-delivered gene therapy modality and rare-disease regulatory strategy (overlap with Genflow's Werner Syndrome orphan approach).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genflow Biosciences

Gene Therapy / Longevity Therapeuticsgenflowbio.com

Genflow Biosciences firmographics

Firmographics
Name
Genflow Biosciences
Legal name
Genflow Biosciences plc
Website
https://genflowbio.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Genflow Biosciences industry classification

Industry
Product category
Gene Therapy / Longevity Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAMANAD
Cell & Gene Therapy for Veterinary Regeneration
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Gene therapy development
  • Longevity therapeutics
  • Age-related disease treatment
  • SIRT6 gene therapy
  • Veterinary longevity

Where Genflow Biosciences is headquartered

Location

Headquarters

HQ city
Gosselies
HQ country
Belgium
HQ region
Europe

Offices3 records

Markets served

Genflow Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Human Gene Therapy (GF-1002): Pre-revenue biotech developing SIRT6 gene therapies targeting age-related diseases including MASH, Werner Syndrome, and sarcopenia. Revenue expected from therapeutic product sales upon regulatory approval.
  2. Animal Health / Veterinary Gene Therapy: Commercialization of canine SIRT6 gene therapy (GF-1004) for companion animal aging. The company is actively pursuing licensing and co-development discussions with Tier-1 animal health companies. Potential for direct commercialization or licensing deals.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Genflow Biosciences product offering

Product offering

Core offering

Genflow Biosciences develops gene therapy candidates that deliver a centenarian variant of the SIRT6 gene via AAV vectors to slow or reverse hallmarks of aging in humans and dogs. Its lead human candidate, GF-1002, targets MASH and other age-related conditions, while GF-1004 is a canine SIRT6 gene therapy evaluated in the SLAB aged-beagle clinical study. The company is pre-revenue and intends to monetize these candidates through licensing and co-development deals with pharmaceutical and animal health partners.

Product overview

Genflow Biosciences is a longevity bioscience company developing gene therapies targeting the aging process through delivery of centenarian SIRT6 gene variants. The company's core product portfolio includes GF-1002 (lead gene therapy for MASH targeting humans), GF-1004 (canine-compatible SIRT6 gene therapy for dog longevity), and the SLAB clinical program evaluating the therapy in aged beagles. The company operates through its SIRT6 mRNA payload platform delivered via lipid nanoparticle (LNP) technology, with clinical programs spanning human MASH treatment, veterinary longevity, muscular diseases (sarcopenia, frailty), and glaucoma. Founded in 2020, the company is headquartered in London with R&D facilities in Belgium and a US office in Cambridge, MA.

Differentiator

Problem solved

Functional benefit

Products and services

  • GF-1002 Lead gene therapy candidate delivering a centenarian variant of the SIRT6 gene via AAV for the treatment of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in human patients with advanced fibrosis. Targeted at pharmaceutical partners for licensing and co-development.
  • GF-1004 Proprietary canine-compatible SIRT6 gene therapy for addressing age-related decline, sarcopenia, and longevity in companion dogs. Evaluated in the SLAB clinical study and targeted at Tier-1 animal health partners for licensing or co-development.
  • SLAB Clinical Program (Sarcopenia and Longevity in Aged Beagles) Proof-of-concept clinical trial program evaluating SIRT6 centenarian gene therapy in 24 aged beagle dogs to assess safety, biological activity, muscle mass preservation, frailty index reduction, and quality-of-life endpoints. Run with Syngene as contract research organisation.
  • SIRT6 mRNA Payload with Acuitas LNP Delivery Technology platform combining Genflow's SIRT6 mRNA payload with Acuitas' proprietary lipid nanoparticle (LNP) delivery system for preclinical evaluation studies supporting future development decisions and partnering arrangements.

Quantifiable outcome

  • All treatment groups in the SLAB study demonstrated superior survival compared to control animals, with no adverse events observed across dosing periods.
  • +3 more outcomes

Companies that use Genflow Biosciences

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Genflow Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Genflow Biosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • CER GroupecoreImplementation/ SI/ Consulting Partner · 30 April 2026Partnership with CER Groupe (Centre d'Enseignement et de Recherche sur les Animaux de Laboratoire) established to support pre-IND development activities for the company's gene therapy programs.
  • Heureka LabscoreImplementation/ SI/ Consulting Partner · 30 April 2026Partnership with Heureka Labs established to support pre-IND development activities for the company's gene therapy programs.
  • Tier-1 Global Animal Health CompaniescoreStrategic or Co-development Partner · 28 April 2026Genflow expanded its engagement with Tier-1 global animal health companies by entering additional confidentiality agreements for the ongoing review of data from its canine SIRT6 gene therapy programme. The expansion follows positive preliminary interim results reported in February 2026 and reflects a broadening base of third-party evaluation of the company's data and underlying technology. These interactions are exploratory in nature and support an ongoing evaluation process for potential licensing and co-development.
  • Acuitas TherapeuticscoreTechnology or Integration · 20 April 2026Strategic technology collaboration with Acuitas Therapeutics, a Vancouver-based leader in lipid nanoparticle (LNP) delivery systems, to integrate Acuitas' proprietary LNP platform with Genflow's SIRT6 mRNA payload for preclinical evaluation studies. The collaboration is fully funded by Acuitas with no cash consideration or dilution to Genflow shareholders, representing independent validation of Genflow's proprietary science. Data generated from preclinical studies will inform future development decisions including delivery optimization and potential partnering arrangements for Genflow's SIRT6 platform targeting age-related diseases.
  • SyngenecoreImplementation/ SI/ Consulting Partner · 1 January 2025Syngene, an independent contract research organisation, manages the dog's longevity clinical trial for Genflow. The trial is controlled, randomised and includes both aesthetic and biological endpoints, running for one year with six months of treatment followed by six months of assessment.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Genflow Biosciences competitors and assessment

Company assessment

Direct peers

  • Unity Biotechnology: Clinical-stage biotech developing senolytic therapeutics for age-related ophthalmologic and musculoskeletal diseases. Comparable aging-disease pipeline orientation and small-cap biotech profile, though Unity's modality is small-molecule rather than gene therapy.
  • Rejuvenate Bio: Gene therapy company developing AAV-delivered interventions targeting age-related disease in dogs and other species. Highly comparable to Genflow given shared modality (AAV gene therapy), shared target species (canine), and shared thesis (treating aging biology rather than single diseases).
  • Loyal for Dogs: Clinical-stage veterinary pharmaceutical company developing drugs (LOY-001, LOY-002) to extend healthspan and lifespan in dogs. Direct peer given Genflow's GF-1004 canine SIRT6 longevity program and shared focus on the companion-dog longevity market.
  • BioAge Labs: Clinical-stage biotech identifying drug targets through analysis of human aging biology and developing therapeutics for age-related metabolic and inflammatory diseases. Direct peer given shared 'aging-as-indication' thesis and pipeline of age-related disease programs.

Emerging players

  • Verve Therapeutics: Clinical-stage biotech developing in vivo gene editing therapies for cardiovascular disease, including MASH-relevant metabolic indications. Comparable in vivo genetic medicine approach and cardiometabolic disease focus, with a gene-editing rather than gene-replacement modality.

Broad incumbents

  • Sarepta Therapeutics: Commercial-stage leader in AAV-based gene therapies for rare genetic diseases. Comparable modality (AAV gene therapy), regulatory pathway (rare disease), and platform-extension logic, though operating at commercial scale versus Genflow's pre-clinical stage.
  • Altos Labs: Well-capitalized private biotech pursuing cellular reprogramming to restore cellular health and reverse disease. Overlapping mission in treating fundamental aging biology, though operating at materially greater scale and with a different core modality.
  • CRISPR Therapeutics: Commercial-stage gene editing company with approved therapy and pipeline spanning rare genetic and regenerative medicine indications. Comparable genetic medicine modality and rare-disease pipeline focus, though at far greater scale and with different editing chemistry.
  • Calico Life Sciences: Alphabet-backed R&D organization focused on understanding the biology of aging and translating insights into therapeutics. Comparable long-horizon aging biology focus, but operates at significantly larger scale and with broader scope than Genflow.
  • Regenxbio: Clinical-stage gene therapy company with proprietary AAV delivery platform and approved/in-development rare-disease programs. Comparable AAV-delivered gene therapy modality and rare-disease regulatory strategy (overlap with Genflow's Werner Syndrome orphan approach).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Genflow Biosciences social profiles

Digital presence

Genflow Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genflow Biosciences leadership team

Management profile

Number of profiles

Profiles5 records

Genflow Biosciences funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genflow Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genflow Biosciences

What does Genflow Biosciences do?

Genflow Biosciences develops gene therapy candidates that deliver a centenarian variant of the SIRT6 gene via AAV vectors to slow or reverse hallmarks of aging in humans and dogs. Its lead human candidate, GF-1002, targets MASH and other age-related conditions, while GF-1004 is a canine SIRT6 gene therapy evaluated in the SLAB aged-beagle clinical study. The company is pre-revenue and intends to monetize these candidates through licensing and co-development deals with pharmaceutical and animal health partners.

Is Genflow Biosciences a public or private company?

Genflow Biosciences is a public company. It is classified as public and is currently operating.

When was Genflow Biosciences founded?

Genflow Biosciences was founded in 2020. It employs 1 to 10 people.

Where is Genflow Biosciences based?

Genflow Biosciences is headquartered in Gosselies, Belgium, in the Europe region.

How does Genflow Biosciences make money?

Two revenue lines are on record. Human Gene Therapy (GF-1002) is the primary driver. The others are animal Health / Veterinary Gene Therapy.

Who are Genflow Biosciences's main competitors?

Direct peers on record are Unity Biotechnology, Rejuvenate Bio, Loyal for Dogs and BioAge Labs. Verve Therapeutics is listed as an emerging player. Broad incumbents are Sarepta Therapeutics, Altos Labs, CRISPR Therapeutics, Calico Life Sciences and Regenxbio.

Does Genflow Biosciences have an API?

No public API is recorded for Genflow Biosciences.

What industry is Genflow Biosciences in?

Genflow Biosciences's product category is Gene Therapy / Longevity Therapeutics. Its primary akta.pro industry code is HLAAACAI, Cardiometabolic & Other Systemic Gene Therapies, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ExameCiência pode fazer cães viverem mais? Corrida pela longevidade chega aos petsUniversities and biotech firms are developing treatments to extend pet lifespans, including genetic therapies for canine heart disease and sarcopenia. The first Animal Longevity Summit in Toronto highlighted these efforts, with companies like Rejuvenate Bio and Genflow Biosciences pursuing genetic approaches. Cryopreservation services are also offered, though no animal has been revived yet.American Banking and Market NewsGenflow Biosciences (LON:GENF) Stock Jumps 1.5% – Still a Buy?Genflow Biosciences shares rose 1.5% on Monday, trading at GBX 1.88 with volume up 10%. The company reported GBX 0.08 EPS for the quarter, with a positive return on equity of 609.63% and a negative net margin of 187.87%.YahooGenflow Biosciences PLC Announces Corporate UpdateGenflow Biosciences announced a Japanese patent allowance for its SIRT6 gene therapy, with all 16 claims granted. The company also signed confidentiality agreements with additional animal health firms to evaluate the therapy for companion animals. It requested a reopening of a regional grant application, with no impact on financial guidance.FinancialContent Business PageGenflow Biosciences PLC Announces Corporate UpdateGenflow Biosciences announced a Japan Patent Office grant decision for its SIRT6 gene therapy, allowing 16 claims. The company also signed confidentiality agreements with additional animal health firms to evaluate the therapy, and requested reopening of a regional grant application. The decision has no impact on financial guidance.Stock TitanGenflow Gets Japan Patent Allowance for 16 ClaimsGenflow Biosciences received a Japan Patent Office grant decision for 16 claims on its SIRT6 gene therapy for age-related diseases. The company also signed confidentiality agreements with additional animal health firms to evaluate the therapy. The decision has no impact on its financial guidance.American Banking and Market NewsGenflow Biosciences (LON:GENF) Stock Price Down 13.3% – Here’s What HappenedGenflow Biosciences stock fell 13.3% to GBX 1.82 on Monday, with trading volume up 452%. The company reported GBX 0.08 EPS for the quarter, with a positive return on equity of 224% and a negative net margin of 148.1%.Longevity.TechnologyGenflow presents interim results from aging-dog SIRT6c studyGenflow Biosciences presented interim results from its SLAB-VET-001 study of SIRT6c gene therapy in 24 aged Beagles at the Animal Longevity Summit in Toronto on 5 October 2026. The randomized, blinded four-arm trial found mean DNA-methylation age reductions of −1.08 years (low-dose pDNA) and −0.48 years (high-dose pDNA) versus −0.07 years in control, with no treatment-related serious adverse events. Intravenous pDNA was selected as the lead delivery modality, with a Day 320 epigenetic read and final histology planned.YahooGenflow Biosciences PLC Announces Presentation of Interim ResultsGenflow Biosciences presented interim results from its SLAB-VET-001 study of SIRT6c gene therapy in aged dogs at the Animal Longevity Summit. The study showed mean epigenetic age reductions of 1.08 and 0.48 years in pDNA arms versus 0.07 in control, with muscle mass gains and no serious adverse events. A second epigenetic-clock read is scheduled at Day 320.FinancialContent Business PageGenflow Biosciences PLC Announces Presentation of Interim ResultsGenflow Biosciences presented interim results of its SLAB-VET-001 study of SIRT6c gene therapy in aged dogs. The study showed mean epigenetic age reductions of -1.08 and -0.48 years in pDNA arms versus -0.07 in control, with muscle mass gains and no serious adverse events. A second epigenetic-clock read is scheduled at Day 320.Stock TitanGenflow Biosciences Reports Interim Dog Trial ResultsGenflow Biosciences presented interim results from its SIRT6c gene-therapy trial in aged dogs, showing mean epigenetic age reductions of 1.08, 0.48, and 0.30 years with low-dose, high-dose, and AAV8 plasmid DNA, respectively, versus 0.07 years with saline. No differences reached statistical significance, and the company plans a Day 320 clock read and an asset sale or out-licence.